BIGBEAR
PHARMACEUTICAL
Dabrafenib is a highly selective BRAF serine-threonine kinase inhibitor and a precision targeted antineoplastic agent.
AuthenticGuaranteeFast DeliveryPrivacy Novartis recently announced updated results from its landmark COMBI-AD clinical trial, demonstrating that in patients with high-risk stage III BRAF-mu···【More】
Update: 02 Apr,2026Source: BigbearViews: 88
On June 22, 2017, the U.S. Food and Drug Administration (FDA) approved the combination of dabrafenib and trametinib (DABRAFENIB® and TRAMETINIB®, Nova···【More】
Update: 02 Apr,2026Source: BigbearViews: 86
The U.S. Food and Drug Administration (FDA) has approved dabrafenib (TAFINLAR®, Novartis Pharmaceuticals Corp.) and trametinib (MEKINIST®, Novartis Ph···【More】
Update: 02 Apr,2026Source: BigbearViews: 84
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
